SAB Biotherapeutics (NASDAQ:SABS) Stock Rating Reaffirmed by HC Wainwright

SAB Biotherapeutics (NASDAQ:SABS)‘s stock had its “buy” rating reiterated by HC Wainwright in a research note issued on Tuesday, Benzinga reports. They presently have a $6.00 target price on the stock. HC Wainwright’s price objective would indicate a potential upside of 30.43% from the company’s previous close.

Separately, Chardan Capital reaffirmed a “buy” rating and issued a $25.00 price target on shares of SAB Biotherapeutics in a research note on Tuesday.

SAB Biotherapeutics Stock Down 5.7 %

SABS stock opened at $4.60 on Tuesday. The company’s 50-day simple moving average is $4.94 and its 200-day simple moving average is $3.12. The company has a debt-to-equity ratio of 0.06, a current ratio of 5.45 and a quick ratio of 5.45. SAB Biotherapeutics has a 52-week low of $4.00 and a 52-week high of $14.50.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. RTW Investments LP purchased a new position in SAB Biotherapeutics in the 4th quarter worth approximately $6,310,000. BVF Inc. IL purchased a new position in SAB Biotherapeutics in the 4th quarter worth approximately $6,310,000. Commodore Capital LP purchased a new position in SAB Biotherapeutics in the 4th quarter worth approximately $1,259,000. Pathstone Family Office LLC purchased a new position in SAB Biotherapeutics in the 3rd quarter worth approximately $319,000. Finally, Pathstone Holdings LLC purchased a new position in SAB Biotherapeutics in the 4th quarter worth approximately $348,000. 7.82% of the stock is owned by hedge funds and other institutional investors.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.